IRCT20140113016200N2招募中2 期
The Evaluation of minocycline effect on reducing the volume of ascites and the tumor markers of VEGF and IL-6 before and after the usage of the drug in patients with resistant malignant ascites
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit(—)
- 性别
- All
入选标准
- •Have metastatic progressive cancer and resistant malignant ascites with no answer to the routine treatments.
- •older than 18 years.
- •Complete written informed consent form in accordance with Ministry of Health guidelines included in this study.
- •Have healthy liver and kidney function.
- •Have estimated lifetime of at least 12 weeks.
- •Should have a measurable disease according to the criteria for evaluation of response to solid tumors (RECIST).
- •At least 3 weeks after the past chemotherapy for improvement of reversible side effects (and at least 6 weeks for chemotherapy drugs that have toxic effects on the stem cells)
- •At least 2 weeks away from previous radiotherapy and in general less than 25% of the bone marrow should be exposed.
- •A patient with previously treated CNS metastasis is eligible only if there is no clinical or radiological evidence of CNS disease progression.
- •Before starting the treatment, complete medical history and physical examination, measurement of height, weight, vital signs, pain score, ECOG score (this test indicates an increase in internal ear pressure in some patients), urine test, pregnancy test, Chest X-ray, ECG, serum biochemical testing including glucose and Cholesterol, electrolytes, urea, creatinine, complete blood count, liver function tests, and measuring tumor markers and VEGF and IL-6 have been done.
排除标准
- •Ascites caused by other factors (e.g., kidney or heart failure, severe liver dysfunction / or occlusion of portal vein and peritoneal inflammation).
- •Severe malnutrition or indigestion (with a BMI less than 19 kg / cm2 and/or hypoproteinemia with serum albumin less than 20 g/ L).
- •Inadequate blood function (Total neutrophil count less than 1500 / MM3 and platelet less than 100,000 / MM3).
- •Severe infection requiring treatment.
- •Coagulopathy or Encephalopathy.
- •Other severe complications that are diagnosed by early examination, such as pregnancy or lactation or psychiatric disorders.
研究者
相似试验
已完成
2 期
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and MechanismsSchizophrenia and Disorders With Psychotic FeaturesNCT02928965University of Manchester207
尚未招募
3 期
Efficacy of add on oral minocycline in children with acute encephalitis syndrome aged 1 month-18 yearsCTRI/2024/07/070172All India Institute of Medical Sciences
进行中(未招募)
1 期
A Pilot Study for the Evaluation of Minocycline in the Treatment of Central Retinal Vein OcclusionsCentral Retinal Vein OcclusionEUCTR2017-001143-12-GBThe National Eye Institute20
进行中(未招募)
1 期
A Pilot Study for the Evaluation of Minocycline in the Treatment of Branch Retinal Vein OcclusionsBranch Retinal Vein OcclusionEUCTR2017-001179-21-GBThe National Eye Institute20
招募中
2 期
Study of efficacy and safety of minocycline in pleurodesisJPRN-jRCTs061210024Toyooka Shinichi19
